Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

2.

Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.

Zhao C, Kim SH, Lee SW, Jeon JH, Kang KK, Choi SB, Park JK.

BJU Int. 2011 Jun;107(12):1943-7. doi: 10.1111/j.1464-410X.2010.09759.x. Epub 2010 Nov 5.

3.

Tadalafil for benign prostatic hyperplasia.

[No authors listed]

Drug Ther Bull. 2013 Aug;51(8):93-6. doi: 10.1136/dtb.2013.8.0199.

PMID:
23949822
4.

Re: tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in asian men.

Kaplan SA.

J Urol. 2014 May;191(5):1345. doi: 10.1016/j.juro.2014.02.068. Epub 2014 Feb 22. No abstract available.

PMID:
24745512
5.
6.

Combined tadalafil and α-blocker therapy for benign prostatic hyperplasia in patients with erectile dysfunction: a multicenter, prospective study.

Lee JY, Park SY, Jeong TY, Moon HS, Kim YT, Yoo TK, Choi HY, Park HY, Lee SW.

J Androl. 2012 May-Jun;33(3):397-403. doi: 10.2164/jandrol.111.013185. Epub 2011 Aug 25.

PMID:
21868753
7.

Efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a meta-analysis.

Dong Y, Hao L, Shi Z, Wang G, Zhang Z, Han C.

Urol Int. 2013;91(1):10-8. doi: 10.1159/000351405. Epub 2013 Jun 25.

8.

[Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia].

Yuan RQ.

Zhonghua Nan Ke Xue. 2012 Dec;18(12):1147-51. Review. Chinese.

PMID:
23405801
11.

A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, Maggi M.

Eur Urol. 2012 May;61(5):994-1003. doi: 10.1016/j.eururo.2012.02.033. Epub 2012 Feb 25. Review.

PMID:
22405510
12.

Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia.

Cantrell MA, Baye J, Vouri SM.

Pharmacotherapy. 2013 Jun;33(6):639-49. doi: 10.1002/phar.1243. Epub 2013 Mar 25. Review.

PMID:
23529917
13.

Tadalafil for the treatment of benign prostatic hyperplasia: when the moment does not add up.

Kaplan SA.

Eur Urol. 2013 Mar;63(3):517-8. doi: 10.1016/j.eururo.2012.11.004. Epub 2012 Nov 10. No abstract available.

PMID:
23158590
14.

Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.

Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L.

J Urol. 2008 Oct;180(4):1228-34. doi: 10.1016/j.juro.2008.06.079. Epub 2008 Aug 22.

PMID:
18722631
15.

Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.

Porst H, Kim ED, Casabé AR, Mirone V, Secrest RJ, Xu L, Sundin DP, Viktrup L; LVHJ study team.

Eur Urol. 2011 Nov;60(5):1105-13. doi: 10.1016/j.eururo.2011.08.005. Epub 2011 Aug 12.

PMID:
21871706
16.

Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action.

Andersson KE, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG, Wyndaele JJ, Melby T, Viktrup L.

Neurourol Urodyn. 2011 Mar;30(3):292-301. doi: 10.1002/nau.20999. Epub 2011 Jan 31. Review.

PMID:
21284024
17.

Monotherapy for comorbid erectile dysfunction and lower urinary tract symptoms: phosphodiesterase inhibitor or α-adrenoceptor antagonist?

Wyllie MG.

BJU Int. 2012 Apr;109(7):965-6. doi: 10.1111/j.1464-410X.2012.10984.x. Epub 2012 Feb 28. No abstract available.

18.

Tadalafil (Cialis) for signs and symptoms of benign prostatic hyperplasia.

[No authors listed]

Med Lett Drugs Ther. 2011 Nov 14;53(1377):89-90. No abstract available.

PMID:
22075669
19.

Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.

Broderick GA, Brock GB, Roehrborn CG, Watts SD, Elion-Mboussa A, Viktrup L.

Urology. 2010 Jun;75(6):1452-8. doi: 10.1016/j.urology.2009.09.093. Epub 2010 Feb 16.

PMID:
20163842
20.

Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment.

Roehrborn CG, Kaminetsky JC, Auerbach SM, Montelongo RM, Elion-Mboussa A, Viktrup L.

BJU Int. 2010 Feb;105(4):502-7. doi: 10.1111/j.1464-410X.2009.08822.x. Epub 2009 Sep 3.

Items per page

Supplemental Content

Write to the Help Desk